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Individual participant data (IPD) from multiple sources allows external valida-
tion of a prognostic model across multiple populations. Often this reveals poor
calibration, potentially causing poor predictive performance in some popula-
tions. However, rather than discarding the model outright, it may be possible
to modify the model to improve performance using recalibration techniques.
We use IPD meta-analysis to identify the simplest method to achieve good
model performance. We examine four options for recalibrating an existing
time-to-event model across multiple populations: (i) shifting the baseline haz-
ard by a constant, (ii) re-estimating the shape of the baseline hazard, (iii)
adjusting the prognostic index as a whole, and (iv) adjusting individual pre-
dictor effects. For each strategy, IPD meta-analysis examines (heterogeneity in)
model performance across populations. Additionally, the probability of achiev-
ing good performance in a new population can be calculated allowing ranking
of recalibration methods. In an applied example, IPD meta-analysis reveals
that the existing model had poor calibration in some populations, and large
heterogeneity across populations. However, re-estimation of the intercept sub-
stantially improved the expected calibration in new populations, and reduced
between-population heterogeneity. Comparing recalibration strategies showed
that re-estimating both the magnitude and shape of the baseline hazard gave
the highest predicted probability of good performance in a new population.
In conclusion, IPD meta-analysis allows a prognostic model to be externally
validated in multiple settings, and enables recalibration strategies to be com-
pared and ranked to decide on the least aggressive recalibration strategy to
achieve acceptable external model performance without discarding existing
model information.
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1 INTRODUCTION
Prognostic models estimate the risk of future outcomes in individuals to aid clinical decision making for both clinicians
and patients.1-3 External validation studies aim to evaluate an existing model’s performance in new data distinct from
that used for model development, in populations with similar or increasingly different case-mix.2-4 Evidence suggests that
there is currently much research waste where prognostic models are concerned, with many newly published models but
relatively few validations of existing models.2,5 Good performance at external validation is an important step toward the
uptake of a model in practice.1-3,6-8 Often external validation reveals poor model performance, however, rather than dis-
carding the model outright, it may be possible to modify the model to improve performance by identifying and addressing
the reasons for poor performance. Poor external validity may be due to various reasons including a poor model develop-
ment strategy, the external population itself (eg, differences in measurement and definition of outcomes or predictors,
or differences in case-mix between external and development samples), or simply due to chance variation, with many
validation studies having small sample sizes.9-11
Development of a new model solely due to poor external performance of an existing model is counterintuitive to
evidence based medicine, as it discards useful information gleaned from previous patient populations.9,12-18 Recalibration
offers a potential solution to poor performance of existing models in new patients; instead of developing a new model
researchers can recalibrate or update existing models, combining information from both previous and new patients.9,18
Methodology in this area is well developed for both binary and time-to-event outcomes.7,12,13,15,17 In particular, approaches
to model recalibration and updating for time-to-event models have been described by van Houwelingen et al, and are
based on parametric models as these allow estimation (and thus recalibration) of the baseline hazard, an essential part in
obtaining absolute risk predictions from a survival model.13,15
Usually, only one dataset is available for external validation and recalibration of a prognostic model. However,
increasingly multiple datasets (eg, from multiple studies or sources) are available for external validation, meaning model
performance can be assessed on multiple occasions and summarized using meta-analysis methods.11 This allows poten-
tial comparison of different recalibration methods across a set of validation studies of differing case-mix. Previous work
has proposed the use of individual participant data (IPD) meta-analysis to compare model implementation strategies
focusing on logistic regression models, and multivariate meta-analysis.14,16,19 Here, our focus is on external validation
of time-to-event models with IPD from multiple studies, specifically flexible parametric (FP) prognostic models. Roys-
ton and Parmar proposed FP models to extend standard parametric survival models to allow more flexibility to capture
realistic baseline hazard shapes.20-22 First, we show that this flexibility allows us to apply different types of recalibra-
tion of the baseline hazard, allowing further options to tailor the model without discarding existing information from
the published model. Second, we propose an IPD meta-analysis methodology that allows us to compare and rank the
impact of these recalibration methods on the predictive performance of a model in new populations, with the aim of
identifying the simplest method to achieve good model performance while re-estimating as little as possible from the
existing model.
The remainder of this article is structured as follows. Section 2 introduces a motivating example where IPD are
available from multiple studies to externally validate a prognostic model in breast cancer. As we assume a prognostic
model already exists, this section also briefly describes the development of an artificial existing model to be used in the
remainder of the article. Section 3 describes the methods and advantages of FP modeling using the Royston-Parmar
approach, and the methods for synthesis of model performance statistics from multiple validation studies. Section 4
then introduces options for model recalibration, and considers how IPD meta-analysis allows these methods to be com-
pared and ranked. Section 5 applies the methods to the motivating example data, and Section 6 concludes with some
discussion.
2 MOTIVATING EXAMPLE IN BREAST CANCER
To illustrate the methods proposed in this article, we use an IPD meta-analysis dataset that contains 5978 breast can-
cer patients, with follow-up ranging from 1 to 10 years (for more information on the original study see Look et al23). It
was formed by pooling datasets from eight centers (hereafter referred to as “studies” for simplicity) across six countries,
with Rotterdam having the largest patient numbers (see Table 1). While the dataset is not publicly available, a closely
related dataset for the Rotterdam data is available at https://www.uniklinik-freiburg.de/imbi/stud-le/multivariable-
model-building.html#c134656.
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T A B L E 2 Predictor effect estimates for the existing model
Predictor Beta SE(Beta) HR Lower 95% CI Upper 95% CI
Age −0.019 0.004 0.981 0.973 0.989
Tumour size
≤ 20 mm ref
20-50 mm 0.472 0.111 1.602 1.399 1.835
>50 mm 0.833 0.271 2.299 1.825 2.897
Lymph nodes
0 ref
1-3 0.647 0.171 1.909 1.602 2.275
4-10 1.260 0.311 3.525 2.965 4.191
>10 1.682 0.620 5.376 4.289 6.739
Menopausal status
Pre ref
Post 0.236 0.130 1.267 1.036 1.548
Adjuvant treatment
No ref
Yes −0.454 0.052 0.635 0.540 0.747
Abbreviations: Beta, regression coefficients; SE, standard error; HR, hazard ratio; CI, confidence interval.
The focus of this article is on using IPD from multiple studies to externally validate and recalibrate an exist-
ing prognostic model that estimates an individual’s probability of recurrence-free survival (RFS) over time from
surgery, defined as the time to recurrence or death from any cause. Though there is also methodological interest
in how to develop a prognostic model utilizing more than one study,14,24 this article focuses solely on how to per-
form external validation and model recalibration of an existing (ie, previously published) prognostic model using
IPD from multiple studies. To this end, for illustrative purposes (and to retain most studies for external valida-
tion), we selected just one study (Rotterdam) as a derivation dataset in which to build an artificial “existing” prog-
nostic model. This ensured that the remaining seven studies were available for use within the external validation
exercise.
For brevity we present only the essential information regarding the artificial existing model here, with extensive
details provided as online supplementary material including: the model development process, sample size consid-
erations, estimated baseline hazard, how the model would be used to estimate individual risk predictions, and the
apparent performance of the model. Details of the estimated predictor effects for the existing model are provided
in Table 2.
We now take this developed model as our existing prognostic model, and rather focus our attention on undertaking
external validation and recalibration of the model in the seven remaining IPD studies. The number of events in these
studies ranged from 80 to 211 per study, with a total of 1019 events across all validation studies (see Table 1). In terms of
validation, current evidence suggests that at least 100-200 events and non-events are required for external validation,25-27
meaning that the breast cancer data is likely sufficient both as a whole (1019 in total) and in each study separately, perhaps
apart from the Nijmegen study which has sample size below 100 events.28 Given the shortest follow-up was 83 months in
the Switzerland study, we truncated follow-up at 72 months so as to reduce the possible influence of long-term survivors
on parameters.29
It is helpful to assess how similar the development and validation cohorts are to identify which validation cohorts
may allow us to measure model transportability or model reproducibility.4 There are a number of ways to assess this
relatedness from simple comparison of summary measures as presented in Table 1, comparing baseline hazard shape and
magnitude, to comparisons of the prognostic index spread and location between cohorts. Such explorations are included
in our online supplementary material.
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3 METHODS FOR EXAMINING PERFORMANCE OF A FP MODEL USING
IPD META-ANALYSIS
In this section, we outline the methods for prognostic modeling using Cox and FP models, and discuss the advantages of
the FP approach for prognostic modeling. We also introduce methods for synthesis of model performance statistics from
multiple validation studies.
3.1 Prognostic models with time-to-event outcomes
3.1.1 Prognostic models using the Cox proportional hazards model
The Cox proportional hazards model is commonly used to develop prognostic models for time-to-event outcomes. The
model can be written as follows,
h(t|xi) = h0(t) exp(PIi) (1)
where the hazard function, h(t| xi), is dependent on the prognostic index, PIi = 𝛽1xi1 + 𝛽2xi2 + · · · + 𝛽pxip (where xip cor-
respond to predictor values for subject i and 𝛽p represent the corresponding predictor effects (log hazard ratios)) and the
baseline hazard function, h0(t), which is equivalent to h(t| xi = 0). The Cox model is referred to as a semiparametric model
because it does not assume (nor estimate) a specific shape for the baseline hazard function.
However, the cumulative hazard function H(t| xi) is crucial to calculating individual survival predictions and so, after
fitting the Cox model, a non-parametric approach or smoothing methods such as splines can be used to estimate the base-
line cumulative hazard function (Ĥ(t|xi = 0) = Ĥ0(t) for brevity). Then the baseline survival function can be obtained by:
Ŝ0(t) = exp(−Ĥ0(t)) (2)
This can be combined with the 𝛽′s from maximum likelihood estimation of the Cox model to calculate survival
probabilities at time t for an individual with covariate values xip using the survival function:
Ŝ(t|xi) = Ŝ0(t)exp(P̂Ii) (3)
3.1.2 Prognostic models using a FP framework
Unlike the Cox model, FP models directly model the shape of the log baseline hazard, removing the need for
post-estimation smoothing.20-22 Standard parametric models assume distributional shapes for the baseline hazard, but
are restricted and often unable to capture realistic hazard functions which may rise and fall over time. Using FP models
allows for increased flexibility in the shape of the baseline hazard through the use of restricted cubic splines to model the
log baseline cumulative hazard function, which leads to the following model for H(t| xi):
ln(H(t|xi)) = spline(ln(t)|𝛾,n) + PIi (4)
where spline(ln(t) | 𝛾 , n) is the restricted cubic spline function for the baseline cumulative hazard and the PIi as before.
Equation (4) is typically estimated using maximum likelihood (for example using the stpm2 module in Stata) with suitable
starting values for the coefficients, 𝛽p, derived from a Cox model with covariates xip.21,22,30
Individual estimates of survival probability can be calculated as before using Equations (2) and (3). We now briefly
explain the derivation of the restricted cubic spline function in Equation (4).
3.1.3 Restricted cubic splines
FP models utilize restricted cubic splines to flexibly model the baseline hazard on the log-cumulative hazard scale. By
fitting cubic splines between given joining points over time, known as knots, FP models can better capture fluctuations
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in the baseline hazard. A smooth function is obtained by constraining the function and its first and second derivatives to
zero at the knots. Restricted cubic splines are used in preference over cubic splines to force the function to also be linear
before the first and after the last knot, so as to ensure a more biologically plausible function in the tails of the distribution
where there is more likely to be sparse data.30 We define a vector of n knots, then the spline function can be written in
terms of parameters 𝛾 and the derived variables zi(t) as below,
spline(ln(t)|𝛾,n) = 𝛾0 + 𝛾1z1(t) + · · · + 𝛾n−1zn−1(t) (5)
z1(t) = ln(t)
zi(t) = (ln(t) − ki)3+ − 𝜆i(ln(t) − k1)3+ − (1 − 𝜆i)(ln(t) − kn)3+ (6)
where the + notation indicates as follows,
(u)+ =
{
u, u > 0
0, u ≤ 0





3.1.4 Advantages of FP models for prognosis
There are several benefits to using FP models over other more traditional parametric or semi-parametric models for
the purpose of prognostic modeling. In particular, semi-parametric models such as the Cox model do not explic-
itly model the baseline hazard, providing only relative effects rather than absolute risk estimates. Being able to
parameterize and estimate the baseline hazard is essential for prognostic model research; first, in order to obtain
individualized absolute risk predictions over time and second, for out-of-sample prediction enabling external val-
idation. We examine the benefits of using FP models further in the online supplementary material, where we
also consider the use of fractional polynomials as an alternative to spline-based parametrizations of the baseline
hazard.31
The focus of this article here onward is on how to validate the predictive performance of an existing FP model using
IPD from multiple studies. The following sections introduce important model performance measures for this purpose,
and explain potential strategies for recalibration of a model to improve performance in external populations.
3.2 Quantifying the predictive performance of a FP model upon external validation
We now consider how to examine the predictive performance of a FP prognostic model upon external validation, in
terms of calibration and discrimination.32 Various statistics can be calculated for these measures.33 In this article, overall
calibration was assessed using the expected (E) and observed (O) survival probabilities, to calculate the ratio (E/O) at
specific time points, as well as overall and time-specific calibration plots across the risk spectrum to summarize calibration
performance over time.1,34 If the E/O statistic at a particular time-point is greater than, or less than one, there is indication
of either systematic over or under prediction, respectively. An E/O statistic of one indicates perfect agreement, either
overall or within specific subgroups.
The discrimination performance of a FP model can be measured using Harrell’s C-statistic,35 and Royston’s
D-statistic.36 Harrell’s C-statistic reveals the separation of predicted risks for those with and without the outcome.35 Roys-
ton’s D-statistic is a measure of separation in survival curves related to the standard deviation of the PI; it can be interpreted
as the log hazard ratio between two groups defined by dichotomizing the PI at the median.36 Royston’s R2D gives a mea-
sure of the proportion of explained variation based on the D-statistic, which is therefore similar to the interpretation of
R2 in linear regression models.36
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3.3 External validation in multiple studies with meta-analysis of performance
Given IPD from multiple studies, the predictive performance of an existing model can be evaluated multiple times. This
leads to multiple estimates for each validation statistic of interest (eg, Harrell’s C-statistic), and so naturally lends itself to
a formal meta-analysis to summarize performance across studies, and examine the magnitude and potential sources of
heterogeneity.14,16,37,38
Let Y i be the estimate of a particular performance statistic of interest where i represents the validation study and let
S2i be the associated variance of Y i, then a random-effects meta-analysis could be used:
Yi ∼ N(𝜃i, S2i ) 𝜃i ∼ N(𝜃, 𝜏
2) (8)
This model can be estimated using restricted maximum likelihood (REML) estimation, and assumes that Y i follows a
normal distribution around the ith study’s true performance, 𝜃i and that 𝜃i is also normally distributed around an average
performance, 𝜃 and a between-study variance 𝜏2. The latter allows for heterogeneity in predictive performance, which
is expected because of changes in case-mix variation, outcome incidence and clinical policies across different popula-
tions and settings.11 A key assumption is normality of the performance estimate in each study, for which appropriate
transformations are needed, in particular the logit(C-statistic), logit(R2D), and ln(E/O) best meet this assumption.19,37,39
Following the meta-analysis, usually of most interest will be the summary (average) performance, 𝜃, and its 95% con-
fidence interval, which is usually derived by 𝜃 ± 1.96 SE(𝜃), where SE(𝜃) is the standard error of 𝜃. Alternative methods
for deriving confidence intervals have been proposed to improve the coverage of confidence intervals in meta-analysis
and could be adopted here also, such as the Hartung-Knapp modification to additionally account for uncertainty in




𝜏2 + SE(𝜃)2 (9)
where k is the number of validation studies in the meta-analysis. This prediction interval infers the potential model per-
formance in a new population/setting similar to those included in the meta-analysis.43,44 A narrower prediction interval
implies more consistent performance in new external populations, and is thus desirable if the model is to be general-
izable outside of a few local settings. Stata code to perform the meta-analysis methods described above is provided as
online supplementary material, for Stata version 15.1.45
4 RECALIBRATION STRATEGIES IN A SINGLE VALIDATION STUDY
If an existing model’s calibration performance is sub-optimal or considered inadequate upon external validation,
then—rather than discarding the model outright—recalibration strategies may be considered to improve it. In this section,
four possible methods are proposed for recalibrating a FP prognostic model within a single validation study, and then we
suggest how IPD meta-analysis methods can be used to compare and rank each of these across multiple studies.
4.1 Recalibration options
The following recalibration methods progressively increase the extent to which the model is adjusted, and closely link to
previously selected methods for a binary outcome example.46 Stata code is provided as online supplementary material,
for each of the methods.
4.1.1 Recalibration Method 1: Keep the same predictor effects and baseline hazard
shape, but change the overall magnitude of the baseline hazard
For this approach, the existing model is applied to participants in the validation study but with the constant term (𝛾0
in Equation (5)) re-estimated within the validation data, to give 𝛾0New so that Equation (4) can be rewritten using,
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spline#(ln(t) | 𝛾 , n) in Equation (10) below. Other parameters are as estimated for the existing model and are not altered.
ln(H(t|xi)) = spline#(ln(t)|𝛾,n) + P̂Ii = 𝛾0New + 𝛾1z1(t) + 𝛾2z2(t) + · · · + P̂Ii (10)
This is the simplest form of recalibration, allowing the baseline hazard in the existing model to be shifted by a constant
factor to better represent the validation population’s baseline hazard. This kind of recalibration is useful when the baseline
hazard rate differs substantially between derivation and validation samples,18 but has the same or similar shape over
time. In logistic regression the constant term can be related to prevalence of disease and so can be easily altered in new
patient populations.14,47 In survival data, it represents a part of the baseline hazard function and so could be interpreted
as a constant shift increasing or decreasing the hazard at any particular time; that is, with different parameterizations, it
could be interpreted as a hazard ratio comparing the hazard rate in the development data to the validation data, under
the assumption that covariates effects do not change.
4.1.2 Recalibration Method 2: Keep the same predictor effects but change the entire
baseline hazard (shape and magnitude)
This approach extends Method 1 to allow adjustment for any differences between the derivation and validation popula-
tions in terms of the overall magnitude (Method 1) and additionally the shape of the baseline hazard. So, for example, the
validation population may have a much earlier and sharper peak in their baseline hazard and a long flattened tail, and
so recalibration of the FP model to capture this shape could improve the performance of the model in external popula-
tions. To implement this method, while keeping predictor effects fixed at their original values, the baseline hazard shape
and magnitude in Equation (4) are completely re-estimated in the validation sample giving a new baseline hazard term,
spline(ln(t) | 𝛾 , n)New as below;
ln(H(t | xi)) = spline(ln(t) | 𝛾,n)New + P̂Ii (11)
When re-estimating the baseline hazard using Method 2, we selected the same number of knots as used in the existing
model, and also forced the same knot locations. However, the method is not restricted to this assumption, and if the shape
of the baseline was more complex in the validation data allowing different numbers of knots or knot locations could be
justified (we provide a sensitivity analysis as online supplementary material).
4.1.3 Recalibration Method 3: Keep the same baseline hazard shape but change
the overall magnitude of the baseline hazard and adjust the prognostic index as a whole
by a constant (𝝓)
In this approach, Method 1 is extended to additionally adjust the PI by a constant scalar term, 𝜙, which is estimated in
the validation data, so that Equation (10) is adjusted as follows,
ln(H(t | xi)) = spline#(ln(t) | 𝛾,n) + (𝜙 × P̂Ii) = 𝛾0New + 𝛾1z1(t) + 𝛾2z2(t) + · · · + (𝜙 × P̂Ii) (12)
As such, Method 3 allows the overall magnitude (but not shape) of the baseline hazard to be corrected, and additionally
scales the predictor effects as a whole by some constant scalar. For example, if predictor effects are systematically too
large (eg, due to uncorrected overfitting during the development of the existing model7), then 𝜙 will be < 1 and predictor
effects will be shrunk.
4.1.4 Recalibration Method 4: Keep the baseline hazard shape and the prognostic
index fixed, but change the overall magnitude of the baseline hazard and re-estimate
the effect of particular predictors
Poor calibration performance in a validation study may relate specifically to changes in the effect of one or a few predictors.
For example, the strength of a single predictor effect such as 𝛽1 may differ in the new population, or the functional form
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of the predictor may have been modeled poorly at development (eg, continuous predictor modeled as categorical).48 In
this case, Method 4 builds on Method 1 by additionally re-estimating 𝛽1 in the validation data to give 𝛽1 New, keeping all
other terms fixed so that Equation (10) is adjusted as follows,
ln(H(t | xi)) = spline#(ln(t) | 𝛾,n) + P̂Ii† + 𝛽1Newx1 = 𝛾0New + 𝛾1z1(t) + 𝛾2z2(t) + · · · + P̂Ii† + 𝛽1Newx1 (13)
where P̂Ii
†
now excludes 𝛽1x1. Method 4 could be extended to allow additional predictor effects to be re-estimated within
the validation data.
Note that if all recalibration methods were combined, this would be equivalent to developing an entirely new model
(while retaining the selected predictors and their functional form from the original model1), and so we do not consider
this.
One possible method to identify predictor effects that may benefit from recalibration would be to measure poten-
tial heterogeneity in the predictor effects when estimated in different studies using meta-analysis (as shown in online
supplementary material). The original model could be fitted within each validation study and, separately for each predic-
tor, the parameter estimates could be pooled in a random-effects meta-analysis using Equation (8). By synthesizing the
effect estimates from each validation study, a summary effect estimate can be obtained, and importantly an estimate of
between-study heterogeneity (𝜏2 as in Equation (8)). If 𝜏2 is large, or similarly if the prediction interval for a predictor’s
effect is wide, then this may signal that calibration would be improved if the predictor effect was re-estimated.
4.2 IPD meta-analysis to summarize performance of recalibration strategies
The recalibration methods described above can be subsequently evaluated and summarized using IPD meta-analysis to
identify the best recalibration strategy16; that is, to find the simplest strategy that leads to the necessary improvement
in the model’s predictive performance within and across studies. When assessing strategies for model recalibration, the
aim is to achieve good model performance on average as indicated by the summary performance statistic 𝜃, as well as
small between-study heterogeneity (𝜏2) when fitting Equation (8). Importantly the 95% prediction interval (Equation
(9)) can also be used to assess the generalizability of the model in new populations similar to those included in the
meta-analysis.43,44
4.3 Comparing and ranking recalibration strategies using multivariate IPD
meta-analysis
While we can formally compare the different recalibration strategies separately for each performance measure of interest,
we may also wish to make decisions based on multiple criteria allowing for the correlation between such measures.16 For
example, we might wish to assess the probability that a recalibration strategy could ensure a C-statistic above 0.65 and an
E/O statistic between 0.95 and 1.05, indicating “good” overall performance.
Snell et al previously proposed a method which can be used to rank such strategies in terms of the joint probability
of achieving a particular level of performance in a new setting or population.16 Extending Equation (8) to a multivariate
meta-analysis allows the joint synthesis of all performance statistics of interest by accounting for both the within- and
between-study correlations. Say for example we wish to jointly synthesize the E/O and C-statistics, then the multivariate





































Here, 𝜃i1 and 𝜃i2 represent the true E/O and C-statistic, respectively, for the ith study, Si is the within-study
variance-covariance matrix for the ith study (assumed known) containing the variances of the estimates (S2i1 and S
2
i2) and
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Study C-statistic R2D D-statistic
Sweden 0.73 (0.68, 0.77) 0.34 (0.23, 0.44) 1.46 (1.12, 1.81)
Lille 0.64 (0.59, 0.69) 0.13 (0.05, 0.23) 0.79 (0.48, 1.11)
Nijmegen 0.66 (0.59, 0.72) 0.18 (0.06, 0.30) 0.94 (0.53, 1.35)
St Cloud 0.65 (0.60, 0.70) 0.15 (0.07, 0.24) 0.86 (0.58, 1.16)
Switzerland 0.72 (0.67, 0.76) 0.30 (0.21, 0.40) 1.36 (1.06, 1.66)
Denmark 1 0.61 (0.57, 0.65) 0.11 (0.04, 0.19) 0.71 (0.42, 1.00)
Denmark 2 0.67 (0.62, 0.71) 0.21 (0.12, 0.32) 1.06 (0.75, 1.40)
Meta-analysis
Summary estimate (95% CI) 0.67 (0.63, 0.70) 0.20 (0.14, 0.28) 1.02 (0.80, 1.24)
95% PI (0.56, 0.76) (0.06, 0.49) (0.34, 1.70)
τ2 0.03 0.22 0.06
I2 (%) 67.75 67.2 68.28
Abbreviations: CI, confidence interval; PI, prediction interval.
T A B L E 3 Performance of the
breast cancer model when applied
to the external validation studies in
terms of the C-statistic, D-statistic,
and R2D
their covariances in the off-diagonal (for example, Si1Si2𝜌Wi(1,2) is the within-study covariance for the E/O and C-statistics,
where 𝜌Wi(1,2) is their within-study correlation caused by estimates derived from the same patients),𝜇1 and𝜇2 represent the
means for the E/O and C-statistics, and
∑
is the between-study variance-covariance matrix containing the between-study
variances (𝜏21 and 𝜏
2
2 ) and their between-study covariances in the off-diagonal as before (where 𝜌B(1,2) is the between-study
correlation induced by differences in study populations and settings).
Joint inferences across multiple performance measures can then be made by accounting for their correlation, using
the multivariate approach as in Equation (14). One can obtain joint probabilistic inferences if we assume the multivariate
t-distribution (with k – 2 degrees of freedom) is an approximate posterior distribution (that is, we assume it is obtained
from a Bayesian analysis with uninformative priors, and give it means, variances and covariances obtained from REML
estimation of Equation (14)) as described by Snell et al.16 For example, one can sample from this assumed joint distribution
many times and calculate the proportion of times performance lies within given parameters (say the C-statistic will be
above 0.65 and E/O will be between 0.95 and 1.05), to derive the joint probability of such performance in a new population.
This probability can then be used to rank recalibration strategies, with the highest probability ranked best.
5 APPLICATION TO THE BREAST CANCER EXAMPLE
The process of external validation and recalibration using IPD meta-analysis is now applied to the breast cancer example
introduced in Section 2. Recall that—for the sake of illustration—one of the studies (Rotterdam) was used to create an
existing model, and thus there were seven studies available for external validation (see Table 1). First, we describe the
performance of the existing model upon external validation, and then work through the model recalibration methods and
compare their external validation performance.
5.1 IPD meta-analysis of external validation performance of existing model
Table 3 gives the summary results from a random-effects meta-analysis (Equation (8)) of the model’s performance in the
seven validation studies, in terms of discrimination (with appropriate transformation of performance statistics as required
see Section 3.3).
Discrimination performance was moderate, with observed C-statistics ranging from 0.61 to 0.73 across validation
studies. An approximate 95% prediction interval suggests the actual C-statistic for the model could range from 0.56 to 0.76
in a single population/setting, most likely due to differences in case-mix distribution across studies (as shown in online
supplementary material). The summary R2D suggests the model explains 20% variation on average, with a 95% prediction
interval of 0.06 to 0.49.
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F I G U R E 1 Calibration plot showing performance of the existing prediction model (at the population-level) before and after
recalibration via Method 1 in the seven validation studies. Dashed grey lines = observed Kaplan-Meier curve. Solid blue lines = prediction
after recalibration using Method 1. Short-dashed red lines = original model predictions before recalibration [Color figure can be viewed at
wileyonlinelibrary.com]
In terms of overall calibration of predicted survival probabilities in each dataset, Figure 1 shows good observed
calibration in one study (“Denmark 2”), but systematic under prediction in five studies (most notably in Swe-
den) and over prediction in the “Denmark 1” study. Therefore, there is considerable between-study heterogene-
ity in the calibration performance of the model. These differences are again likely due to differences in case-mix
distribution, and baseline hazard across studies, which is explored further within the online supplementary
material.
Figure 2 shows the summary calibration performance based on univariate random-effects meta-analysis of E/O at
various time points since surgery. It is clear that, on average across studies, the model’s under-prediction of outcome risk
increases over the first 4 years, with E/O about 0.9 at 4 years onward. Furthermore, the between-study heterogeneity in
calibration performance increases over time as reflected by a widening prediction interval for E/O, for example of 0.7 to
1.3 by 4 years.
5.2 IPD meta-analysis of external validation performance after recalibration
The previous section showed that the breast cancer model had large heterogeneity in predictive performance across the
seven external validation studies. Average performance was also shown to be suboptimal, particularly at increased years
from surgery, and so the model is unlikely to be robust in all populations of potential application. Therefore, we now
consider methods for recalibration of the existing model to improve model performance, and aim to identify the best
recalibration strategy using meta-analysis methods.
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F I G U R E 2 Calibration performance of the existing model
over time based on univariate random-effects meta-analysis of
the E/O statistic (at years 1 to 6 separately), showing summary
(average) E/O in the seven external validation studies, alongside
95% confidence (CI) and prediction intervals (PI) [Color figure
can be viewed at wileyonlinelibrary.com]
5.2.1 Recalibration Method 1 calibration performance
Calibration performance was substantially improved through use of recalibration Method 1, where the intercept of the
baseline cumulative hazard’s spline function was re-estimated for each study (see Figure 1). The updated model’s predic-
tions using Method 1 are, overall across the entire set of individuals, extremely close to the observed Kaplan-Meier curve
in each study (Figure 1, solid lines), in contrast to the (sometimes large) miscalibration for predictions from the existing
model before recalibration (Figure 1, short-dashed lines).
A forest plot for the E/O statistic measured at 3 years post-surgery using all methods is given in Figure 3, showing
poor calibration of the existing model, and stark improvement after applying Method 1. For example, the E/O statistic at
3 years for the Sweden validation study is 0.81, which is equivalent to a patient’s predicted probability of survival being
19% lower than the truth. However after recalibration of the overall magnitude of the baseline hazard using Method 1,
this under prediction is reduced to just 2%, as E/O is 0.98 (see Figure 3).
5.2.2 Recalibration Method 2 calibration performance
Recalibration Method 2 builds on Method 1 by additionally allowing the shape of the baseline cumulative hazard to be
re-estimated, which leads to further improvements compared to the existing model’s performance. For example, after
recalibration of the magnitude of the baseline hazard using Method 1 the summary E/O statistic was 0.990 (0.981, 0.999)
at 1 year post-surgery equivalent to under prediction of 1%, with heterogeneity across validation studies performance (I2
= 48%). However, after additional recalibration of the whole baseline cumulative hazard (magnitude and shape) using
Method 2, the models’ predictions are (at the population-level) perfect with a summary E/O = 0.998 (0.992, 1.005) and
no heterogeneity (𝜏2=0, I2 = 0%; see Table 4).
The prediction intervals calculated from the random effects meta-analysis were much narrower after Methods 1 (95%
PI: 0.966, 1.016) and 2 (95% PI: 0.989, 1.007) compared with the existing model (95% PI: 0.908, 1.052), indicating very little
potential variation in calibration performance in new populations where recalibration can be implemented. There was
evidence of heterogeneity in calibration performance at all time points post-surgery (𝜏2 = [0.001, 0.024]), observed for the
existing model, and this was reduced to zero heterogeneity after use of recalibration Method 2 in particular (see Table 4).
5.2.3 Recalibration Method 3 calibration performance
Method 3 builds on Method 1 as described in Section 4, and thus calibration performance remained superior to the
existing model. Notably Method 3 appeared to negate the additional improvement made by Method 2, pulling per-
formance back in line with that seen under Method 1, such that there is still some miscalibration in E/O statistics
(see Figure 3).
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F I G U R E 3 Random-effects
meta-analysis of calibration
performance (E/O at 3 years
post-surgery) of the existing model in all
validation studies split by recalibration
method. Top panel shows performance
of the original existing model in the
validation studies (ie, before any
recalibration) [Color figure can be
viewed at wileyonlinelibrary.com]
5.2.4 Recalibration Method 4 calibration performance
Recalibration Method 4 is the same as Method 1 but also allows re-estimation of a particularly heterogeneous pre-
dictor effect (see Section 4). To identify such a predictor in the existing model, we applied a separate random-effects
meta-analysis of each predictor’s effects in the external validation dataset. That is, we re-fitted the existing model in
each validation study separately and all estimates and standard errors of the regression coefficients were stored. Next a
random-effects meta-analysis of log hazard ratio estimates was performed for each predictor in turn to quantify the hetero-
geneity in the predictor’s effect across the validation studies using Equation (8). This process identified the tumor size pre-
dictor had a notably heterogeneous effect, with a between-study variance of 𝜏2 = 0.242 and I2 = 62.5% (see Figure 4), and
it was therefore re-estimated while holding other predictor effects fixed (ie, values kept the same as in the original model).
As Method 4 builds on Method 1, the magnitude of the baseline cumulative hazard is also updated alongside the
re-estimated predictor effect for tumor size. The revised model has calibration performance similar to that for Method 3,
with increased miscalibration in the Denmark 2 study compared to Method 2 (see Figure 3).
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E/O (1 year) Summary effect (CI) 95% PI 𝛕2 I2 (%)
Existing model 0.977 (0.957, 0.999) (0.908, 1.052) 0.001 89.695
Method 1 0.990 (0.981, 0.999) (0.966, 1.016) 0 47.726
Method 2 0.998 (0.992, 1.005) (0.989, 1.007) 0 0
Method 3 0.990 (0.981, 0.999) (0.966, 1.014) 0 45.394
Method 4 0.990 (0.981, 0.999) (0.966, 1.015) 0 47.380
E/O (3 year) Summary effect (CI) 95% PI 𝛕2 I2 (%)
Existing model 0.934 (0.871, 1.001) (0.726, 1.200) 0.008 95.140
Method 1 0.986 (0.971, 0.999) (0.967, 1.005) 0 0
Method 2 0.997 (0.983, 1.012) (0.978, 1.016) 0 0
Method 3 0.986 (0.971, 1.000) (0.967, 1.005) 0 0
Method 4 0.985 (0.971, 0.999) (0.967, 1.004) 0 0
E/O (6 year) Summary effect (CI) 95% PI 𝛕2 I2 (%)
Existing model 0.919 (0.816, 1.036) (0.598, 1.414) 0.024 95.817
Method 1 1.005 (0.983, 1.027) (0.976, 1.035) 0 0
Method 2 0.998 (0.976, 1.019) (0.969, 1.027) 0 0
Method 3 1.006 (0.984, 1.029) (0.977, 1.036) 0 0
Method 4 1.005 (0.983, 1.027) (0.976, 1.034) 0 0
C-statistic Summary effect (95% CI) 95% PI 𝛕2 I2 (%)
Existing model 0.667 (0.634, 0.699) (0.563, 0.760) 0.001 68.60
Method 1 0.667 (0.634, 0.699) (0.563, 0.760) 0.001 68.60
Method 2 0.667 (0.634, 0.699) (0.563, 0.760) 0.001 68.60
Method 3 0.667 (0.634, 0.699) (0.563, 0.760) 0.001 68.60
Method 4 0.667 (0.635, 0.699) (0.570, 0.760) 0.001 68.20
Abbreviations: CI, confidence interval; PI, prediction interval.
T A B L E 4 Comparison of
univariate random effects
meta-analysis results for each
recalibration method in terms of
both calibration (E/O statistic) and
discrimination performance
(C-statistic)
5.2.5 Discrimination performance after recalibration
Table 4 also shows the discrimination performance of the model after applying each recalibration method. It is clear that
discrimination performance was unaffected by recalibration Methods 1 to 3, as expected because these methods do not
alter the relative ranking of the PI.9 Discrimination is strongly influenced by case-mix in the validation cohort, and Method
4 directly adjusts the PI by re-estimating an individual predictor effect, but in this example we considered adjustment of
only one predictor (tumor size). Harrell’s C-statistic varied by 0.01 in the 95% CI and PI, but did not alter in terms of the
summary performance estimate even after recalibration with Method 4 (see Table 4 and online supplementary material
for additional results). Further, there was no change in the heterogeneity in discrimination performance across validation
studies after any recalibration method.
5.3 Overall ranking of recalibration strategies
We now fit a multivariate meta-analysis jointly synthesizing the E/O and C-statistics to compare the recalibration strate-
gies as described in Section 4.3. Post-estimation, the joint probability of achieving a C-statistic > 0.65 and an E/O statistic
between 0.95 and 1.05 (at 1 year) was calculated for each recalibration method in turn by drawing 10 000 samples from a
multivariate t-distribution. The ranking of these joint probabilities is presented in Figure 5, where all recalibration meth-
ods showed high probabilities, close to one, whereas fitting the existing model without recalibration had a much lower
predicted probability of 0.713 of achieving the specified performance criteria. The highest predicted probability was for
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F I G U R E 4 Random-effects
meta-analysis of tumour size regression
coefficient [ln(HR)] from each
validation study [Color figure can be
viewed at wileyonlinelibrary.com]
F I G U R E 5 Ranking of recalibration methods by the
expected probability of good performance in a new
population, defined as a C-statistic > 0.65 & 0.95 < E/O
< 1.05. Based on 10,000 draws from a multivariate
t-distribution using parameters from a multivariate
meta-analysis of C-statistic and E/O performance across the
validation studies available in the breast cancer dataset
[Color figure can be viewed at wileyonlinelibrary.com]
Method 2 with a probability of almost 1. Crucially, however, the simpler Method 1 gives practically the same improve-
ment, and so is the one we recommend for applying the model in practice (as it only requires the magnitude of the baseline
hazard to be re-estimated in each country of application).
5.4 Further evaluations of calibration at the individual level using pseudo-values
Throughout the manuscript, we have focused on population level calibration of the model; however, it is also impor-
tant that the model performs well across the risk spectrum, that is, the model must calibrate well for patients at
high and low risk, not only on average. To assess calibration across the risk spectrum, we examined time-specific cal-
ibration plots using both groupings and individual event probabilities to discern more subtle miscalibrations, using
Stata packages “pmcalplot” and “stcoxcal”.34,49 We used pseudo-values to derive the observed event probabilities for
individuals at a specific timepoint, though alternative approaches have recently been proposed.34,50 Examining these
plots showed a similar pattern of miscalibration across the risk spectrum to that seen at the population level in
Figure 1, with recalibration improving performance substantially (further details provided in online supplementary
material).
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6 DISCUSSION
We examined the use of recalibration methods for improving the performance of an existing survival model at external
validation, when multiple validation studies are available. In the applied example, when making predictions using the
existing model directly, discrimination performance was moderate, but calibration was often poor with substantial over
and under prediction across studies, as is common in new patient populations, due to changes in case-mix variation and
baseline hazard rate (as explored in the online supplementary material).8,9,51,52 Various recalibration strategies were eval-
uated to address this using IPD meta-analysis methodology. The findings showed that recalibration of the magnitude
of the baseline hazard gave large improvements in the calibration performance of the model. The method is simple, as
it only requires re-estimation of the intercept in the validation study. Similar improvements have been shown through
recalibration of the intercept in logistic prediction model examples.9,12,47 The other methods investigated (recalibration
of the baseline hazard shape, prognostic index, or individual predictors), showed little additional improvement on adjust-
ment of the intercept alone. Discrimination performance was unaltered by such methods as adjustment of baseline risk
or hazard does not materially alter the relative rankings of the prognostic index.9
The premise of our work lies in identifying which recalibration method is most appropriate in new settings (ie, greatest
improvement in performance with simplest model updating method), as such other applications may find another recal-
ibration method more beneficial than that identified for this case study. Previous work has proposed the use of a closed
testing procedure to identify the best recalibration method to improve performance while avoiding overfitting for logistic
prediction models46; such an approach could also be evaluated for time-to-event models in further work. However, here
we instead used a novel ranking system based on the joint probability of achieving “good” summary performance (derived
after a multivariate meta-analysis) in terms of both calibration and discrimination of the model in the external popula-
tion. This adds to the proposed methodology by allowing for the multivariate nature of model performance, where both
discrimination and calibration are equally important for a model to be useful. In our case study, the rankings reinforced
conclusions drawn from the IPD meta-analysis results, highlighting that simpler methods of recalibration could achieve
good model performance without needing to throw away information from the existing model, and prevents researchers
from simply developing an entirely new model.
One limitation of recalibration methods is the level of information required about the existing model for recalibration
to be possible. Here FP models were used because they naturally allow flexibility to investigate the recalibration of various
parts of the model and at various time-points; however in practice many published prognostic models are Cox models.
This hinders the use of even simple recalibration methods because it is very rare that an estimate of the baseline hazard
(or baseline survival) is published,53 and this is essential to individualized prediction and recalibration.1,30 Despite this,
Royston and Altman have laid out detailed methods for external validation of a Cox model elsewhere.1 For example,
even if authors have only presented S0(t) at a few specific time points, it is possible to make predictions and gain some
assessment of calibration performance (though this is rarely reported).1 The strategies proposed here could be applied to
Cox model examples with the exception of Method 1, instead recalibration would need to begin with Method 2 allowing
complete recalibration of the baseline hazard in the validation sample.
In the motivating example, IPD was available from seven validation studies with clustering based on countries. How-
ever, the methods discussed here are equally applicable to any clustering variable, for example when using e-health
databases which often contain clustering by center or region.11 In the example, recalibration of the intercept to spe-
cific clusters provided the required improvement in model performance (while re-estimating fewest parameters from
the original model). Practically, this means that for every new population a new intercept must be calculated for the
existing model (to achieve best performance), and so the relevant data must be available and large enough to estimate
the intercept reliably.54-56 Previous research has also found that models using study-specific intercepts may give great-
est performance; for example, Wynants et al recommended the use of conditional model predictions in clustered data
as they perform well at both the population and center level in terms of both calibration and discrimination.14,16,57 Our
four methods are not exhaustive, and other options could be considered. In particular, temporal recalibration may be
important in fields of rapid medical advancement, allowing recalibration of the baseline hazard using a specific recent
time window.58,59
Importantly recalibration in any form could strictly be viewed as a new model, which itself requires external validation
in new data, in potentially different patient populations, new settings, different geographical locations or at different
times.1,8,32,60 This could mean a never-ending cycle of recalibration followed by external validation, with then further
recalibration, and so on. Further research of this issue is needed, but is likely dependent on the purpose of the model in
practice. For example, recalibration methods such as those discussed here may work best when the aim is to tailor a model
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to a specific practice in which the model will then be used routinely, making an emphasis on further external validation
in new settings potentially less important.
In conclusion, we have presented methods for the recalibration of FP prognostic models, and proposed methodology
using IPD meta-analysis to examine the ability of the various recalibration methods, to improve an existing prognostic
model’s performance in external validation datasets. Summary measures including summary discrimination and cali-
bration statistics, heterogeneity in performance statistics, prediction intervals, and joint probability ranking can inform
selection of the best recalibration strategy for particular external populations. In particular this methodology can be
used to decide on the least aggressive recalibration strategy to achieve acceptable external model performance without
discarding existing model information. Stata code is available to perform the proposed methodology.
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